Atossa Genetics (NASDAQ:ATOS) Stock Price Crosses Below 200-Day Moving Average – Should You Sell?

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $6.42 and traded as low as $1.81. Atossa Genetics shares last traded at $1.83, with a volume of 466,738 shares traded.

Analysts Set New Price Targets

A number of research firms have issued reports on ATOS. Weiss Ratings downgraded shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Ascendiant Capital Markets lowered their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, April 10th. Finally, HC Wainwright boosted their price target on shares of Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $24.50.

Atossa Genetics Stock Performance

The company has a 50-day moving average price of $4.61 and a 200-day moving average price of $6.28. The firm has a market capitalization of $15.07 million, a P/E ratio of -0.55 and a beta of 1.24.

Atossa Genetics (NASDAQ:ATOS) last released its earnings results on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.12). Equities analysts predict that Atossa Genetics Inc. will post -4.3 EPS for the current year.

Institutional Trading of Atossa Genetics

A number of hedge funds have recently modified their holdings of the company. &PARTNERS acquired a new position in Atossa Genetics during the fourth quarter valued at approximately $25,000. Hudson Bay Capital Management LP acquired a new stake in Atossa Genetics in the second quarter worth $26,000. JPMorgan Chase & Co. raised its holdings in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares during the period. Bank of America Corp DE boosted its position in shares of Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after purchasing an additional 35,629 shares in the last quarter. Finally, XTX Topco Ltd boosted its position in shares of Atossa Genetics by 581.2% during the fourth quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after purchasing an additional 144,412 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.